Merck's MK-2214 drug received fast-track designation from the Food and Drug Administration for treatment of Alzheimer's disease. The Rahway, N.J., company said Monday that it would present data this ...
Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Novo Nordisk's semaglutide fails in Alzheimer's trials Trials aimed for 20% slowing of cognitive decline in Alzheimer's More details to be released at December 3 meeting COPENHAGEN, Nov 24 (Reuters) - ...
Growing evidence suggests that the key to treating Alzheimer's is catching it in its earliest stages. Now scientists have developed a promising new drug that seems to be effective at stalling the ...
New research suggests Alzheimer’s may start far earlier than previously thought, driven by a hidden toxic protein in the brain. Scientists found that an experimental drug, NU-9, blocks this early ...
A new study has identified three existing medications that could be repurposed to treat or prevent Alzheimer's disease. The research, led by the University of Exeter, is published in Alzheimer's ...
Hosted on MSN
Doctors discover a new dementia that often gets misdiagnosed and 6.5 million people are at riskDoctors are growing concerned that a dementia mimicking Alzheimer’s has led to millions of misdiagnosed seniors, complicating treatment and care. LATE (Limbic-predominant Age-related TDP-43 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results